4 days ago
Enveric Biosciences Inc. (NASDAQ:ENVB) on Wednesday said that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals Inc. against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent) has been withdrawn.
The action follows Enveric's filing of a Request for Discretionary Denial of the petition. As a result, there are no remaining challenges currently pending against Enveric's patent.
Enveric's ‘276 patent, "Halogenated psilocybin derivatives and methods of using", includes claims that appear relevant to the bretisilocin (GM-2505) molecule currently in clinical trials.
In August 2025, Gilgamesh filed a PGR petition in the United States Patent and Trademark Office, Patent Trial and Appeal Board (PTAB) against Enveric's '276 patent.
